サンテゾーン点眼液（０．０２％）
基本情報
| 項目 | 値 |
|---|---|
| DrugBank ID | DB01234 |
| エビデンスレベル | L5（計算予測のみ） |
| 予測適応症数 | 100 |
| 日本商品名（例） | アフタゾロン口腔用軟膏０．１％, アフタゾロン口腔用軟膏０．１％（選）, オイラゾンクリーム０．０５％ |
承認適応症（KEGG）
乾癬、掌蹠膿疱症、慢性円板状エリテマトーデス、毛孔性紅色粃糠疹、菌状息肉症、天疱瘡群、家族性良性慢性天疱瘡、類天疱瘡
予測適応症（TxGNN）
以下は TxGNN モデルにより予測された潜在的新適応症です。スコアが高いほど関連性が高いと予測されています。
| # | 適応症 | スコア | ソース |
|---|---|---|---|
| 1 | punctate epithelial keratoconjunctivitis | 99% | DL |
| 2 | rheumatic heart disease | 99% | DL |
| 3 | miliary tuberculosis | 99% | DL |
| 4 | adrenocortical insufficiency | 99% | DL |
| 5 | nephrotic syndrome | 99% | DL |
| 6 | heparin-induced thrombocytopenia (disease) | 99% | DL |
| 7 | autoimmune hemolytic anemia | 99% | DL |
| 8 | spondyloarthropathy, susceptibility to | 99% | DL |
| 9 | adrenogenital syndrome | 99% | DL |
| 10 | fetal erythroblastosis | 99% | DL |
| 11 | Addison disease | 99% | DL |
| 12 | chronic primary adrenal insufficiency | 99% | DL |
| 13 | pemphigus | 99% | DL |
| 14 | mantle cell lymphoma | 99% | DL |
| 15 | Trichinellosis | 99% | DL |
| 16 | acquired thrombocytopenia | 99% | DL |
| 17 | tenosynovitis | 99% | DL |
| 18 | granulomatous slack skin disease | 99% | DL |
| 19 | familial adrenal hypoplasia with absent pituitary luteinizing hormone | 99% | DL |
| 20 | Stevens-Johnson syndrome | 99% | DL |
| 21 | alopecia areata | 99% | DL |
| 22 | alopecia mucinosa | 99% | DL |
| 23 | telogen effluvium | 99% | DL |
| 24 | Quinquaud's folliculitis decalvans | 99% | DL |
| 25 | alopecia antibody deficiency | 99% | DL |
| 26 | hereditary hypotrichosis with recurrent skin vesicles | 99% | DL |
| 27 | alopecia-intellectual disability-hypergonadotropic hypogonadism syndrome | 99% | DL |
| 28 | atrichia with papular lesions | 99% | DL |
| 29 | alopecia universalis onychodystrophy vitiligo | 99% | DL |
| 30 | prolapse of lacrimal gland | 99% | DL |
| 31 | idiopathic steroid-sensitive nephrotic syndrome | 99% | DL |
| 32 | sporadic idiopathic steroid-resistant nephrotic syndrome | 99% | DL |
| 33 | PAGOD syndrome | 99% | DL |
| 34 | Sjogren syndrome | 99% | DL |
| 35 | 46,XY disorder of sex development | 99% | DL |
| 36 | articular cartilage disease | 99% | DL |
| 37 | transient arthropathy | 99% | DL |
| 38 | de Quervain disease | 99% | DL |
| 39 | ganglion or cyst of synovium/tendon/bursa | 99% | DL |
| 40 | shoulder impingement syndrome | 99% | DL |
| 41 | Behcet syndrome arthropathy | 99% | DL |
| 42 | Stevens-Johnson syndrome/toxic epidermal necrolysis overlap syndrome | 99% | DL |
| 43 | necrobiosis lipoidica | 99% | DL |
| 44 | ankylosis (disease) | 99% | DL |
| 45 | lacrimal gland neoplasm | 99% | DL |
| 46 | persistent polyclonal B-cell lymphocytosis | 99% | DL |
| 47 | vertebral joint disease | 99% | DL |
| 48 | disorder of GPI anchor biosynthesis | 99% | DL |
| 49 | exostosis | 99% | DL |
| 50 | lipoid nephrosis | 98% | DL |
（上位50件を表示。全100件の予測があります）
免責事項
これらの予測は研究目的のみであり、医療アドバイスを構成するものではありません。 臨床応用には必ず適切な検証が必要です。